DBV Technologies (NASDAQ:DBVT) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Other equities research analysts have also recently issued research reports about the company. Deutsche Bank boosted their price target on DBV Technologies from $46.00 to $56.00 in a research note on Sunday, October 8th. Morgan Stanley cut DBV Technologies from an “overweight” rating to an “equal weight” rating in a research note on Monday, October 23rd. Leerink Swann set a $49.00 price target on DBV Technologies and gave the company an “outperform” rating in a research note on Monday, October 23rd. Societe Generale cut DBV Technologies from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. Finally, Barclays lowered their price target on DBV Technologies from $58.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, October 23rd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. DBV Technologies presently has a consensus rating of “Hold” and an average price target of $49.63.

Shares of DBV Technologies (DBVT) opened at $25.05 on Thursday. DBV Technologies has a 12 month low of $20.58 and a 12 month high of $50.57.

A number of institutional investors have recently made changes to their positions in DBVT. Sectoral Asset Management Inc boosted its position in DBV Technologies by 34.2% during the second quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock worth $6,398,000 after purchasing an additional 45,653 shares during the period. Janus Henderson Group PLC bought a new stake in DBV Technologies during the second quarter worth approximately $90,724,000. Dynamic Technology Lab Private Ltd bought a new stake in DBV Technologies during the second quarter worth approximately $222,000. Sabby Management LLC bought a new stake in DBV Technologies during the second quarter worth approximately $1,339,000. Finally, Alps Advisors Inc. boosted its position in DBV Technologies by 9.1% during the third quarter. Alps Advisors Inc. now owns 47,477 shares of the company’s stock worth $2,015,000 after purchasing an additional 3,964 shares during the period. 46.92% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/01/20/dbv-technologies-dbvt-stock-rating-lowered-by-bidaskclub.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.